Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -24.51% is 100% above its 3-year average of -6108.86%, around the middle of its 3-year range (-33166.67%–29571.19%).
99.42% above its 12-month average of -4192.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -48.73%.
NET PROFIT MARGIN
-24.51%
NET PROFIT MARGIN AVG TTM
-4192.01%
NET PROFIT MARGIN AVG 3Y
-6108.86%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+99.42%
CURRENT VS 3Y AVG
+99.60%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-9326.92%
vs the sector median at left
Septerna Inc
Market Cap
$1.61B
Net Profit Margin
-24.51%
TTM Avg
-4192.01%
3Y Avg
-6108.86%
5Y Avg
N/A
Market Cap
$1.61B
Net Profit Margin
-579.10%
TTM Avg
-408.42%
3Y Avg
-273.23%
5Y Avg
-333.72%
Market Cap
$1.60B
Net Profit Margin
-1350.73%
TTM Avg
-1059.67%
3Y Avg
-1046.38%
5Y Avg
-742.65%
Market Cap
$1.62B
Net Profit Margin
-13.50%
TTM Avg
-22.64%
3Y Avg
-31.77%
5Y Avg
-40.07%
Market Cap
$1.63B
Net Profit Margin
10.82%
TTM Avg
2.93%
3Y Avg
-1.36%
5Y Avg
-5.99%
Market Cap
$1.59B
Net Profit Margin
-140.43%
TTM Avg
-164.31%
3Y Avg
-442.76%
5Y Avg
-354.21%
Market Cap
$1.57B
Net Profit Margin
-753.60%
TTM Avg
-123.57%
3Y Avg
-563.59%
5Y Avg
-375.72%
Market Cap
$1.54B
Net Profit Margin
-87.60%
TTM Avg
-755.85%
3Y Avg
-377.93%
5Y Avg
-1051.76%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Septerna Inc (SEPN) | $1.61B | -24.51% | -4192.01% | -6108.86% | N/A |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -579.10% | -408.42% | -273.23% | -333.72% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 3.13% | 0.65% | -0.01% | 1.74% |
| uniQure N.V. (QURE)vs › | $1.60B | -1350.73% | -1059.67% | -1046.38% | -742.65% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -13.50% | -22.64% | -31.77% | -40.07% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 10.82% | 2.93% | -1.36% | -5.99% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -140.43% | -164.31% | -442.76% | -354.21% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -753.60% | -123.57% | -563.59% | -375.72% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -87.60% | -755.85% | -377.93% | -1051.76% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 80.56% | 35.15% | 48.19% | 54.54% |
Operating Margin
-175.8%
Net Profit Margin
-24.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -48.73% |
| 2026-03-31 | -32.56% |
| 2025-12-31 | -44.52% |
| 2025-09-30 | 38.02% |
| 2025-06-30 | -20872.27% |
| 2025-03-31 | -9806.39% |
| 2024-12-31 | -9749.06% |
| 2024-09-30 | -11660.80% |
| 2024-06-30 | -4443.51% |
| 2024-03-31 | -4468.77% |
| 2023-12-31 | 29571.19% |
| 2023-09-30 | -33166.67% |
